Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label vemurafenib study in BRAF V600-mutant radioactive iodine-resistant papillary thyroid cancer
NL-OMON39294Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vemurafenib in papillary thyroid cancer (PTC) (2 cohorts), sponsored by Roche. Primary endpoint: Best overall response rate. Started Oct 2011; status: active, not recruiting.
02
Drugs
vemurafenib
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on NL-OMON39294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39294.